Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.3.1.900
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Revenues:      
Biocatalyst product sales $ 11,376 $ 13,064 $ 20,423
Biocatalyst research and development 25,599 14,945 6,868
Revenue sharing arrangement 4,829 7,298 4,631
Total revenues 41,804 35,307 31,922
Costs and operating expenses:      
Cost of biocatalyst product revenues 6,586 9,726 14,554
Research and development 20,673 22,755 31,606
Selling, general and administrative 22,315 21,937 26,908
Total costs and operating expenses 49,574 54,418 73,068
Loss from operations (7,770) (19,111) (41,146)
Interest income 19 18 60
Other expense (168) (234) (304)
Loss before income taxes (7,919) (19,327) (41,390)
Benefit from income taxes (338) (256) (87)
Net loss $ (7,581) $ (19,071) $ (41,303)
Net loss per share of common stock, basic and diluted (usd per share) $ (0.19) $ (0.50) $ (1.08)
Weighted average common shares used in computing net loss per share of common stock, basic and diluted (shares) 39,438 38,209 38,231